Skip to main content
OpenTrials
Completed

NCT Number: NCT05894317

Vascular Access Complications for Therapeutic Apheresis in Nephrology

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vascular Access Complication Anti-Glomerular Basement Membrane Disease Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Apheresis Related Complication Autoimmune Diseases Cardiovascular Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Immune System Diseases Kidney Diseases Lung Diseases Lung Diseases, Interstitial Male Urogenital Diseases Nephritis Respiratory Tract Diseases Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Systemic Vasculitis Urogenital Diseases Urologic Diseases Vascular Diseases Vasculitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Central Hospital

Nancy, 54000, France

About this study

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions.

The investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in North East France.

Nephrologics indications include :

  • acute or active antibody mediated rejection (ABMR),
  • Goodpasture disease,
  • ANCA vasculitis,
  • thrombotic microangiopathy (TMA),
  • Focal segmental glomerulosclerosis (FSGS),
  • HLA or ABO desensitization for kidney transplantation.

Data inclusion period is from June 2020 to June 2022.

The aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the North East France. Te investigators will study the risk factors that are associated with this complications.

The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients in nephrology receiveing apheresis treatment by filtration or double filtration

Exclusion criteria

  • apheresis treatment for other indications
  • centrifugation apheresis treatment

Treatment and study plan

Primary outcomes

  1. Vascular access Complication (catheter or AVF/AVG thrombosis/infection) rate in therapeutic apheresis among nephrological diseases

    Time frame: june 2020 june 2022

    Percent of patient with Vascular access Complication

Secondary outcomes

  1. Description of population enrolled

    Time frame: june 2020 june 2022

    Description of population treated by therapeutic apheresis in Northeast France

  2. Comparison of complications rate with literature datas

    Time frame: june 2020 june 2022

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Vascular Access Complications for Therapeutic Apheresis in Nephrology : a Retrospective Observational Study in North-East France.

Acronym: VACTANE

Important dates

Study start
2020
Primary completion
2022
Study completion
2025
First posted
Jun 8, 2023
Registry last updated
Feb 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.